17.12.2025 • News

IMCD Germany: Garbotz to Succeed Wallstein

As of January 1, 2026, Christoph Garbotz will be Managing Director for IMCD Germany and responsible for the management of the Germany, Austria, Southeast Europe and Switzerland region.

Photo
Christoph Garbotz, IMCD Managing Director for Germany as of 1 January 2026, replacing Lars Wallstein
© IMCD

IMCD, a global partner for the distribution and formulation of specialty chemicals and ingredients, announced the appointment of Christoph Garbotz as Managing Director for Germany and responsible for the management of the Germany, Austria, Southeast Europe and Switzerland region. He will step into the role on 1 January 2026, replacing Lars Wallstein who has been Managing Director of IMCD Germany since September 2019 and decided to leave the company. 

Christoph Garbotz brings a strong international track record across commercial and leadership roles outside and within IMCD. He joined IMCD in 2020 as Business Unit Manager for Pharmaceuticals, Beauty and Personal Care, and Home Care and I&I in Germany. In 2022, he became Managing Director of IMCD Switzerland where he led the integration of DCS Pharma and strengthened IMCD’s position in the Swiss market. Most recently, he has served as Director Principal Management for the Pharmaceuticals Business Group. 

Company

Logo:

IMCD Deutschland GmbH

Konrad-Adenauer-Ufer 41-45
50668 Cologne
Germany

Company contact







Interview

Leading Transformation
The Path to Sustainable Growth

Leading Transformation

As Executive Vice President of International Chemicals since early 2024, Antje Gerber has been steering Sasol through a pivotal reset—focused on resilience, innovation, and bold sustainability goals.

Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read